DC-S239 is a selective histone methyltransferase SET7 inhibitor with an IC 50 value of 4.59 μM. DC-S239 also displays selectivity for DNMT1 , DOT1L , EZH2 , NSD1, SETD8 and G9a. DC-S239 has anticancer activity.
Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Histone Methyltransferase
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.